The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Shares of Charles River Laboratories International, Inc. (CRL) traded over 3% lower on Friday morning after the U.S. Food and ...

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, ...

Human-Based Lab Models: The FDA will promote the use of lab-grown human “organoids” and organ-on-a-chip systems that mimic ...

Late Thursday, the US Food and Drug Administration revealed it is taking a ground-breaking step to advance public health by ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and autoimmunity.

The FDA is phasing out an animal testing requirement for monoclonal antibody therapies in favor of testing drugs on ...

Biocon subsidiary, Biocon Biologics, on Thursday announced the approval of its antibody Jobevne by the U.S. Food and Drug ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. | As it advances a ...

Available abstracts will be shared on INOVIO's website following presentations.